3AV-26002-11656
3 vaccinations
1 coded response
3 check-ins
0 free-text entries
0 call cases
- Sex
- Female
- Age at first dose
- 0-4
- ZIP prefix
- 554 / MN
- Registered
- 2022-12-28
- Relationship
- Child or adolescent in my care
- Guardian
- ZAK-32026-69041
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2022-09-07
Dose 1 — Pfizer-BioNTech
-
2022-09-28
Dose 2 — Pfizer-BioNTechCo-administered: Flu
-
2022-11-23
Dose 3 — Pfizer-BioNTech
-
2022-12-28
Registered in v-safe
- 2022-12-29
- 2023-01-04
-
2023-05-24
Survey response — 6 months, dose 3, under 3MedDRA: Nasopharyngitis, Respiratory symptom — Feeling: GoodMedDRA releases: 2024-11
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2022-09-07 | Pfizer-BioNTech | No |
| 2 | 2022-09-28 | Pfizer-BioNTech | Flu |
| 3 | 2022-11-23 | Pfizer-BioNTech | No |
Free text
None.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Nasopharyngitis | · | · | ✓ |
| SD | Respiratory symptom | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release